Showing results (91-100 of 142) with videos related to

Sort By:
Pageof 15
Journal of Cardiac Failure|November 4, 2022
Minimal Clinically Important Differences in 6-Minute Walk Test in Patients With HFrEF and Iron DeficiencyMuhammad Shahzeb Khan, Stefan D Anker, Tim Friede, et al.
The New England Journal of Medicine|November 19, 2009
Ferric carboxymaltose in patients with heart failure and iron deficiencyStefan D Anker, Josep Comin Colet, Gerasimos Filippatos, et al.
European Journal of Heart Failure|January 31, 2023
Impact of ferric carboxymaltose for iron deficiency at discharge after heart failure hospitalization: a European multinational economic evaluationPhil McEwan, Cale Harrison, Rhona Binnie, et al.
Clinical Epidemiology|July 6, 2023
Is Age the Most Important Risk Factor in COVID-19 Patients? The Relevance of Comorbidity Burden: A Retrospective Analysis of 10,551 HospitalizationsDamià Valero-Bover, David Monterde, Gerard Carot-Sans, et al.
European Journal of Internal Medicine|March 28, 2024
Serum potassium abnormalities, renin-angiotensin-aldosterone system inhibitor discontinuation, and clinical outcomes in patients with chronic cardiovascular, metabolic, and renal conditions: A population-based analysisSantiago Jiménez-Marrero, Miguel Cainzos-Achirica, David Monterde, et al.
European Journal of Heart Failure|March 13, 2022
Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiencyJaved Butler, Muhammad Shahzeb Khan, Tim Friede, et al.
Biomolecules|September 27, 2025
Serum Growth Differentiation Factor 15 (GDF15) Levels Reflect Ischemic Etiology in Heart Failure Patients with Iron Deficiency: A Cross-Sectional StudyMarta Tajes, Maria Del Mar Ras-Jiménez, Josefa Girona, et al.
European Journal of Heart Failure|March 25, 2022
Responder analysis for improvement in 6-min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiencyStefan D Anker, Piotr Ponikowski, Muhammad Shahzeb Khan, et al.
European Journal of Heart Failure|August 4, 2023
Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSEJoão Pedro Ferreira, Jonathan P Blatchford, John R Teerlink, et al.
Circulation|April 4, 2022
Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE TrialMikhail N Kosiborod, Christiane E Angermann, Sean P Collins, et al.
Pageof 15